Biosimilars fever hits snag

Korea’s policymakers dreamed that biosimilars are poised to exploit the opportunity arising from expiring marketing exclusivity on the leading blockbuster biologics in Korea.

However, the biologics environment is already facing increasing competitive and pricing pressures and the model of launching incrementally improved next generation molecules is likely over.

Consequently, biobetters ...